Aegis Therapeutics To Present At The "13th Annual Drug Delivery Summit" In New Brunswick, NJ, September 22-23, 2008

Main Category: Conferences
Article Date: 24 Aug 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present a talk entitled: "New Technologies Expanding Practical Clinical Uses of Peptides, Proteins, and Other Macromolecular Therapeutics" at Insight's "13th Annual Drug Delivery Summit." The conference will be held on September 22-23, 2008 at the Hyatt Regency, New Brunswick, NJ. Dr. Edward T. Maggio, President and CEO of Aegis, will present studies on the application of Aegis' Intravail® non-invasive drug delivery technology, and Aegis' ProTek® protein stabilization technology to specific peptide, protein, and small molecule therapeutics.

Information about the conference may be obtained from the following website.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.

Aegis Therapeutics

Article adapted by Medical News Today from original press release.
Visit our conferences section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Aegis Therapeutics. "Aegis Therapeutics To Present At The "13th Annual Drug Delivery Summit" In New Brunswick, NJ, September 22-23, 2008." Medical News Today. MediLexicon, Intl., 24 Aug. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/118926.php>

APA
Aegis Therapeutics. (2008, August 24). "Aegis Therapeutics To Present At The "13th Annual Drug Delivery Summit" In New Brunswick, NJ, September 22-23, 2008." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/118926.php.

Please note: If no author information is provided, the source is cited instead.


Conferences

Most Popular Articles



Follow Our Conferences News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Conferences Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »